GLP-1 therapies have now advanced far beyond their origins. Originally developed as treatments for type 2 diabetes, they have become one of the most influential forces reshaping consumer behaviour, healthcare delivery and pharmaceutical strategy.
This shift is now visible far beyond the clinic. Appetite-modifying medications such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), along with emerging oral and multi-agonist therapies, are influencing everything from food purchasing to health system planning.
Their impact reflects a shift in clinical innovation, changing patient expectations and heightening system level pressures. This all indicates that a new era in metabolic health is already upon us.
Check out the rest of the feature here
